Thrombolysis of occluded arterial bypass grafts.
Seventy-eight patients with 87 thrombosed grafts or arteries were treated by direct intraarterial infusion of streptokinase or urokinase. Initial success rate in treatment of occluded grafts (60%) was nearly identical to native artery occlusion (63%), and nearly twice as high for urokinase (76%) compared with streptokinase (43%). There was no statistically significant difference in complication rates between native vessel occlusion and thrombosed grafts, or between urokinase- and streptokinase-treated groups. Nineteen of 29 grafts (66%) remain patent after an average 11-month followup.
D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006801:Humans; D013300:Streptokinase / Q000627:therapeutic use; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator